This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Przyklenk, K. Articles by Kloner, R. A. Search for Related Content PubMed PubMed Citation Articles by Przyklenk, K. Articles by Kloner, R. A.

EXPERIMENTAL STUDY

Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis

^a Heart Institute, Good Samaritan Hospital, and Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles, California, USA

Manuscript received April 11, 2000; revised manuscript received July 17, 2000, accepted September 11, 2000.

Reprint requests and correspondence: Dr. Karin Przyklenk, Heart Institute/Research, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, California 90017-2395
karinp{at}dnamail.com

OBJECTIVES

Our aim was to determine whether sildenafil citrate (Viagra) unfavorably alters coronary perfusion in canine models of coronary artery stenosis.

BACKGROUND

Concern has been raised that sildenafil may exacerbate ischemia in patients with coronary artery disease. However, the effects of sildenafil on coronary perfusion are largely unexplored.

METHODS

Using anesthetized dogs, a micromanometer constrictor was applied to either an intact coronary artery (model of stable hypoperfusion: Protocol 1) or a site of arterial injury (model of recurrent platelet-mediated thrombosis: Protocol 2). After monitoring coronary flow for 1 h, dogs received two escalating, clinically relevant doses of sildenafil or placebo. Perfusion was assessed during the initial hour pretreatment, for 1 h following dose 1 and 1 h following dose 2 by measuring the area of the flow-time profile, normalized to baseline flow x 60 min. Interaction between sildenafil and adenosine-mediated inhibition of platelet aggregation was evaluated by in vitro platelet aggregometry (Protocol 3).

RESULTS

In Protocol 1, flow-time area was maintained at 50% to 60% of baseline in both placebo- and sildenafil-treated groups. In Protocol 2, controls exhibited an expected modest, temporal adenosine-mediated improvement in flow-time area (from 40 ± 5% to 61 ± 7%; p < .05) while in contrast, perfusion in sildenafil-treated dogs remained unchanged (37 ± 6% vs. 33% to 35% before vs. after treatment). In vitro aggregometry confirmed that sildenafil rendered platelets refractory to the inhibitory effects of adenosine receptor stimulation.

CONCLUSIONS

Sildenafil did not exacerbate ischemia in canine models of coronary stenosis. However, in the setting of recurrent thrombosis, sildenafil-treated dogs were apparently unresponsive to the platelet inhibitory effects of endogenous adenosine.

Abbreviations and Acronyms   cAMP = adenosine 3',5'-cyclic monophosphate   cGMP = guanosine 3',5'-cyclic monophosphate   CBF = coronary blood flow   CFVs = cyclic variations in coronary blood flow   LAD = left anterior descending coronary artery   NO = nitric oxide   PDE 5 = phosphodiesterase 5   RMBF = regional myocardial blood flow

This article has been cited by other articles:

				T. Reffelmann and R. A. Kloner Phosphodiesterase 5 inhibitors: are they cardioprotective? Cardiovasc Res, July 15, 2009; 83(2): 204 - 212. [Abstract] [Full Text] [PDF]

				G. D. Lewis, C. Witzke, P. Colon-Hernandez, J. L. Guerrero, K. D. Bloch, and M. J. Semigran Sildenafil Improves Coronary Artery Patency in a Canine Model of Platelet-Mediated Cyclic Coronary Occlusion After Thrombolysis J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1471 - 1477. [Abstract] [Full Text] [PDF]

				S. G. Raja and S. H. Nayak Sildenafil: Emerging Cardiovascular Indications Ann. Thorac. Surg., October 1, 2004; 78(4): 1496 - 1506. [Abstract] [Full Text] [PDF]

				A. Das, R. Ockaili, F. Salloum, and R. C. Kukreja Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1455 - H1460. [Abstract] [Full Text] [PDF]

				K. M. Fox, U. Thadani, P. T.S. Ma, S. D. Nash, Z. Keating, M. A. Czorniak, H. Gillies, M. Keltai, and on behalf of the CAESAR I investigators Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina Eur. Heart J., December 2, 2003; 24(24): 2206 - 2212. [Abstract] [Full Text] [PDF]

				T. Reffelmann and R. A. Kloner Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation Cardiovasc Res, August 1, 2003; 59(2): 441 - 449. [Abstract] [Full Text] [PDF]

				T. Reffelmann and R. A. Kloner Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease Circulation, July 15, 2003; 108(2): 239 - 244. [Full Text] [PDF]

				F. Salloum, C. Yin, L. Xi, and R. C. Kukreja Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase-Dependent Pathway in Mouse Heart Circ. Res., April 4, 2003; 92(6): 595 - 597. [Abstract] [Full Text] [PDF]

				R. Ockaili, F. Salloum, J. Hawkins, and R. C. Kukreja Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1263 - H1269. [Abstract] [Full Text] [PDF]